|
|
Post by mnkdfann on Aug 29, 2019 18:39:14 GMT -5
More than likely, it was just an old paper the authors had been trying to publish in a better journal for years. Then, after many rejections, from a bunch of better journals, they sent their paper to this second or third rate journal.
It is not a fake journal, and some papers in MDPI journals are quite good. Appearing in a MDPI journal does not automatically make a paper bad or useless.
Probably other better journals just weren't interested in a paper describing an old study of a product that is by now off the market.
My guess is that the only reason Afrezza even got a mention is that the authors made a minimal effort to update the paper so some referee might find the paper slightly more topical and timely.
|
|
|
|
Post by mnkdfann on Aug 28, 2019 19:54:24 GMT -5
I'm not sure what 'selling puts on their shares' means. One can certainly sell covered calls on shares that are owned. But selling puts on shares held long doesn't really make sense. It doesn't work that way. If you want to sell covered puts, you sell puts against shares you hold short. If you don't believe me, listen to Charles: www.schwab.com/active-trader/insights/content/manage-risk-covered-calls-and-covered-puts(Of course, your broker may also allow you to sell uncovered puts.) |
|
|
|
Post by mnkdfann on Aug 27, 2019 21:51:23 GMT -5
again why are people worrying about getting to pre split pps of $55 that will not happen for many many years. that's 11 bill m/c.. we did not have a m/c of 11 bill in 2014.. For comparability we need to get to pre split market cap of $22 buck or so.. so we can compare logically. It depends what one wants to compare. People may be interested in knowing how long until they break even. Or come close to breaking even. For that, people look to the share price, not the market cap. |
|
|
|
Post by mnkdfann on Aug 23, 2019 7:51:50 GMT -5
That having been stated, and regardless of Sanofi's pricing, in my opinion preparing for negotiations of foreign pricing is about the ONLY valid reason for initially keeping Afrezza priced at a premium in the USA during launch in the US and international markets. International drug agencies will use US prices to calculate the target price for a drug distributed in their countries. Years down the road, after adoption in foreign markets, can the US price be lowered. Is that still mostly the case though? News from earlier this month: globalnews.ca/news/5746469/health-canada-drug-price-regulations/"Under the new rules, Canada will change the list of countries the federal drug price regulator, the Patented Medicine Prices Review Board (PMPRB), compares domestic prices to, dropping the United States and Switzerland where prices are highest." It has been reported widely in the past that Canada has the second highest drug prices and only because Canada included the U.S. in the basket of comparison countries. That would suggest that a lot of (most?) nations had already stopped including the U.S. example before Canada recently decided not to. A recent RAND report studied half a dozen nations, and only Canada (at the time) considered U.S. pricing. France, Netherlands, and Spain, for example, certainly did not. The RAND report is linked to in this article: www.aei.org/publication/a-closer-look-at-international-reference-pricing-for-prescription-drugs/ |
|
|
|
Post by mnkdfann on Aug 22, 2019 9:27:24 GMT -5
|
|
|
|
Post by mnkdfann on Aug 21, 2019 8:26:38 GMT -5
|
|
|
|
Post by mnkdfann on Jul 27, 2019 22:38:40 GMT -5
I didn't really understand the sarcasm by Fann.. and I blew it off.. Sarcasm? I have to assume this must be a cultural thing, because there was absolutely no sarcasm intended. I'm just gonna shut up now. |
|
|
|
Post by mnkdfann on Jul 27, 2019 16:44:59 GMT -5
Based on Sweedee's previous posts, I thought the problem now was Alzheimer's related. Nothing really to do with insurance or SOC or atherosclerosis. <insert puzzled smiley> That is about the most callous thing I have ever seen posted on these boards!!!!! WTF!!!!! Have you ever had someone close to you suffer a stroke? And, since when does having dementia wipe out the effects of diabetes (though not applicable here)? You should be ashamed for even thinking such a thing, much less posting it...... How on earth is it callous? Perhaps you should reread her own posts on the topic of her father and family before you attack me. If I misread something Sweedee wrote (it is possible) my bad, but my takeaway from Sweedee's posts, such as these mnkd.proboards.com/post/179856mnkd.proboards.com/post/179938was that her father's (non-diabetic) health and life arrangement issues were complicating his diabetes management (and that the issues causing her father difficulty now were not the ones some others had suggested in prior posts). I smh at how quick some are to take offense at innocent comments. My advice (take it or leave it) is to assume the best of people, not the worst, and you will get farther and be happier in life. |
|
|
|
Post by mnkdfann on Jul 26, 2019 21:35:48 GMT -5
Based on Sweedee's previous posts, I thought the problem now was Alzheimer's related. Nothing really to do with insurance or SOC or atherosclerosis. <insert puzzled smiley>
|
|
|
|
RLS
Jul 26, 2019 13:13:21 GMT -5
Post by mnkdfann on Jul 26, 2019 13:13:21 GMT -5
For a pick me up read the RLS website. I noticed just the other day how gender diverse the Advisory Board was ... then I realised the Board photo was a stock image, and the Board is actually solely men. www.receptorlife.com/scientific-advisory-board |
|
|
|
Post by mnkdfann on Jul 24, 2019 21:44:27 GMT -5
Hilarious. It was an award winner. The negative commentary on the commercial is all the more reason I keep buying. Boom time soon. MO It’s a shame your post after this one was deleted...It was spot on, especially about the reason I continue to have faith. If failure was a certainty, there would be no need for them to be here. I felt the opposite. I liked the first two posts. But questioning the ISS site and its reports in the third post was, I think, a little goofy. |
|
|
|
Post by mnkdfann on Jul 22, 2019 0:09:28 GMT -5
I seriously doubt we get 5.25%. I would expect a lot near 9.5% or higher. Mannkind is a micro-cap - that's not a compelling loan candidate. They are a micro cap with small revenues and debt. Let's see what MNKD can do. I also believe they will have several offers and this time will not be forced into a bad deal. Several people already explained it: mnkd.proboards.com/post/184445"SENS had around a 100 million cash, about 40 million debt , and Roche as a partner. I don't believe Mannkind's situation is quite analogous." mnkd.proboards.com/post/184449"SENS product has not been on the market for five years. Also their product is not selling way below expectations and has a large percentage of doctors who want no business with Afrezza." |
|
|
|
Post by mnkdfann on Jul 20, 2019 18:44:39 GMT -5
Vdex appears to have been inspired by Stranger Thing's recent homage to 'The Never-Ending Story':
JULY 20th
Email sent requesting meeting with Mannkind Executive Team members Patrick McCauley (Chief Commercial Officer), David Kendall (Chief Medical Officer) and Steven Binder (Chief Financial Officer). - Awaiting response.
|
|
|
|
Post by mnkdfann on Jul 18, 2019 21:34:39 GMT -5
Too lazy to read the hfm document. Did they state if they already have financing lined up, or if they would try to get financing after they make a deal with mnkd? To me this is all that matters. Thank you. 🤷♀️🤦🏼♀️ This was not a meeting about a Vdex deal. This was for the shareholders who actively want change. The discussion about the Vdex deal has to be with the Board of Directors. Any chance you can expand on what the radical way outside the box idea was? "There was a suggestion by M/R that perhaps the company should consider something radically different, way outside the box, since it appears the conventional has been tried." |
|
|
|
Post by mnkdfann on Jul 18, 2019 18:00:41 GMT -5
Meeting notes are now posted at the HFM site. Well. I'm not overwhelmed with the report. But it sounds as though it was at least a friendly meeting. |
|
